MCID: VSC003
MIFTS: 59

Visceral Leishmaniasis

Categories: Immune diseases, Infectious diseases

Aliases & Classifications for Visceral Leishmaniasis

MalaCards integrated aliases for Visceral Leishmaniasis:

Name: Visceral Leishmaniasis 12 15
Leishmaniasis, Visceral 44 73
Kala-Azar 12 3
Infection by Visceral Leishmaniasis 12
Leishmaniasis Visceral 55

Classifications:



External Ids:

Disease Ontology 12 DOID:9146
ICD10 33 B55.0 B55.9
ICD9CM 35 085.0
MeSH 44 D007898
NCIt 50 C34771
SNOMED-CT 68 48115004
UMLS 73 C0023290

Summaries for Visceral Leishmaniasis

Disease Ontology : 12 A leishmaniasis that is the most severe form of the disease caused by protozoan parasites of the Leishmania genus, resulting in the infection of the internal organs such as liver, spleen and bone marrow. The symptoms include fever, weight loss, and an enlarged spleen and liver.

MalaCards based summary : Visceral Leishmaniasis, also known as leishmaniasis, visceral, is related to leishmaniasis and hemophagocytic lymphohistiocytosis. An important gene associated with Visceral Leishmaniasis is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Amphotericin B and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, bone and t cells, and related phenotypes are cellular and digestive/alimentary

Wikipedia : 76 Visceral leishmaniasis (VL), also known as kala-azar (UK: /�?k�?ːl�? �?�?z�?ːr/), black fever, and... more...

Related Diseases for Visceral Leishmaniasis

Diseases related to Visceral Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 408)
# Related Disease Score Top Affiliating Genes
1 leishmaniasis 32.1 CXCL8 FOXP3 IFNG IL10 IL2 IL4
2 hemophagocytic lymphohistiocytosis 31.0 CXCL8 IFNG IL10 TNF
3 uveitis 30.8 IFNG IL10 IL4 TNF
4 arthritis 30.8 CXCL8 IFNG IL10 TNF
5 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.6 FOXP3 IFNG IL10
6 lymphopenia 30.6 FOXP3 IFNG IL2
7 keratitis, hereditary 30.6 TLR2 TLR4 TLR9
8 anterior uveitis 30.5 TLR2 TLR4 TNF
9 sleeping sickness 30.4 IL10 NOS2 PGD
10 acquired immunodeficiency syndrome 30.4 ALB IFNG IL10 IL2 TNF
11 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 30.4 FOXP3 IFNG IL10 IL2 IL4
12 lepromatous leprosy 30.4 IFNG IL10 IL2 TLR2 TNF
13 human immunodeficiency virus infectious disease 30.3 IFNG IL10 IL2 TLR9 TNF
14 leptospirosis 30.3 CXCL8 IFNG IL10 TLR2 TNF
15 connective tissue disease 30.2 IFNG IL10 TLR9 TNF
16 crohn's disease 30.2 IL10 SLC11A1 TLR9 TNF
17 mixed connective tissue disease 30.2 IFNG IL10 TNF
18 fascioliasis 30.2 ALB IFNG IL10
19 tuberculous meningitis 30.1 CXCL8 TLR2 TNF
20 toxoplasmosis 30.1 IFNG IL10 IL4 TLR2 TLR4 TLR9
21 hepatopulmonary syndrome 30.0 ALB NOS2 TNF
22 hemorrhagic fever 30.0 ALB IFNG IL10 TNF
23 myeloma, multiple 30.0 ALB CXCL8 IL2 TLR9 TNF
24 mucocutaneous leishmaniasis 30.0 IL10 TLR9 TNF
25 chagas disease 29.9 CXCL8 IFNG IL10 IL2 NOS2 TLR2
26 aphthous stomatitis 29.8 IL10 IL2 IL4 TLR2 TNF
27 autoimmune disease 29.8 FOXP3 IFNG IL10 IL2 IL4 SLC11A1
28 pulmonary tuberculosis 29.8 IFNG IL10 IL2 IL4 SLC11A1 TLR2
29 viral infectious disease 29.8 CXCL8 IFNG IL10 IL2 IL4 TLR9
30 bacterial sepsis 29.7 CXCL8 IL10 NOS2 TLR4 TNF
31 leprosy 3 29.7 ALB IFNG IL10 IL2 IL4 SLC11A1
32 rheumatoid arthritis 29.7 CXCL8 FOXP3 IFNG IL10 IL2 IL4
33 pneumonia 29.6 CXCL8 IL10 TLR2 TLR4 TLR9 TNF
34 cutaneous leishmaniasis 29.6 FOXP3 IFNG IL10 IL4 LMLN PGD
35 psoriasis 29.5 CXCL8 IFNG IL10 IL2 IL4 TLR9
36 meningitis 29.5 ALB CXCL8 IFNG IL10 TLR2 TLR9
37 trypanosomiasis 29.4 ALB CXCL8 IFNG IL10 IL2 IL4
38 bacterial infectious disease 29.4 CXCL8 IFNG IL10 SLC11A1 TLR2 TLR4
39 filariasis 29.4 ALB IFNG IL10 IL2 TLR2 TLR4
40 systemic lupus erythematosus 29.3 ALB CXCL8 FOXP3 IFNG IL10 IL2
41 malaria 29.3 ALB CXCL8 FOXP3 IFNG IL10 IL2
42 common variable immunodeficiency 29.3 FOXP3 IFNG IL10 IL2 IL4 TLR2
43 multiple sclerosis 29.2 FOXP3 IFNG IL10 IL2 IL4 NOS2
44 kala-azar 2 12.5
45 kala-azar 3 12.5
46 kala-azar 1 11.5
47 pancytopenia 10.4
48 cephalosporin allergy 10.4 IFNG IL10
49 immune-complex glomerulonephritis 10.4
50 pneumococcal meningitis 10.4

Graphical network of the top 20 diseases related to Visceral Leishmaniasis:



Diseases related to Visceral Leishmaniasis

Symptoms & Phenotypes for Visceral Leishmaniasis

MGI Mouse Phenotypes related to Visceral Leishmaniasis:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.33 ALB EEF2 FOXP3 IFNG IL10 IL2
2 digestive/alimentary MP:0005381 10.31 ALB FOXP3 IFNG IL10 IL2 IL4
3 hematopoietic system MP:0005397 10.31 FOXP3 IFNG IL10 IL2 IL27 IL4
4 homeostasis/metabolism MP:0005376 10.29 ALB FOXP3 IFNG IL10 IL2 IL27
5 immune system MP:0005387 10.27 FOXP3 IFNG IL10 IL2 IL27 IL4
6 growth/size/body region MP:0005378 10.25 EEF2 FOXP3 IFNG IL10 IL2 IL4
7 mortality/aging MP:0010768 10.24 ALB EEF2 FOXP3 IFNG IL10 IL2
8 endocrine/exocrine gland MP:0005379 10.18 ALB FOXP3 IFNG IL10 IL2 IL4
9 liver/biliary system MP:0005370 10.1 ALB FOXP3 IFNG IL10 IL2 IL4
10 integument MP:0010771 10.03 FOXP3 IFNG IL10 IL4 NOS2 TLR2
11 neoplasm MP:0002006 9.97 ALB IFNG IL10 IL2 NOS2 SLC11A1
12 normal MP:0002873 9.86 ALB FOXP3 IFNG IL10 IL4 TLR2
13 renal/urinary system MP:0005367 9.76 ALB FOXP3 IFNG IL4 NOS2 TLR2
14 respiratory system MP:0005388 9.61 FOXP3 IFNG IL10 IL2 IL4 NOS2
15 vision/eye MP:0005391 9.23 FOXP3 IFNG IL10 IL2 IL4 NOS2

Drugs & Therapeutics for Visceral Leishmaniasis

Drugs for Visceral Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1397-89-3 5280965 14956
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Miltefosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58066-85-6 3600
4
deoxycholic acid Approved Phase 4,Phase 3,Not Applicable 83-44-3 222528
5
Paromomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1263-89-4, 7542-37-2 165580
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
Meglumine antimoniate Experimental, Investigational Phase 4,Early Phase 1 133-51-7
8 Liposomal amphotericin B Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Amphotericin B, deoxycholate drug combination Phase 4,Phase 3,Not Applicable
15 Cholagogues and Choleretics Phase 4,Phase 3,Not Applicable
16 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
17 Anesthetics Phase 4
18 Antimony Sodium Gluconate Phase 4,Phase 3,Phase 2,Phase 1
19 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20
Pentamidine Approved, Investigational Phase 3 100-33-4 4735
21
Aluminum sulfate Approved Phase 2, Phase 3,Phase 3 10043-01-3
22
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
23
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
24
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
25 Tocotrienol Investigational Phase 3 6829-55-6
26 Antiviral Agents Phase 3,Not Applicable
27 Adjuvants, Immunologic Phase 2, Phase 3,Phase 3
28 Vaccines Phase 2, Phase 3,Phase 3,Phase 1
29 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
30 Peripheral Nervous System Agents Phase 3
31 Analgesics Phase 3
32 Anti-HIV Agents Phase 3
33 Anti-Retroviral Agents Phase 3
34 Analgesics, Non-Narcotic Phase 3
35 Interleukin-2 Phase 3
36 Vitamins Phase 3,Not Applicable
37 Tocotrienols Phase 3
38 Tocopherols Phase 3
39 Fat Emulsions, Intravenous Phase 2
40 Soy Bean Phase 2
41 Pharmaceutical Solutions Phase 2
42 Soybean oil, phospholipid emulsion Phase 2
43 Parenteral Nutrition Solutions Phase 2
44 Immunoglobulins Phase 1, Phase 2,Not Applicable
45 Antibodies Phase 1, Phase 2,Not Applicable
46 Thromboplastin Phase 1
47
Acetylcysteine Approved, Investigational Not Applicable 616-91-1 12035
48
Coal tar Approved Not Applicable 8007-45-2
49
Neomycin Approved, Vet_approved Not Applicable 1404-04-2 8378
50
Erythromycin Approved, Investigational, Vet_approved Not Applicable 114-07-8 12560

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Unknown status NCT01566552 Phase 4 AMBISOME
2 Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
3 Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
4 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
5 Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh Completed NCT03311607 Phase 4 AmBisome
6 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4 Sodium stibogluconate
7 Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
8 Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Unknown status NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
9 An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
10 Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
11 Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study Completed NCT01360762 Phase 3 Pentamidine
12 Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
13 Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
14 To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
15 Replacement of Insecticides to Control Visceral Leishmaniasis (VL) Completed NCT01644682 Phase 3
16 Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
17 Combination Therapy in Indian Visceral Leishmaniasis Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
18 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
19 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
20 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
21 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
22 Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
23 Miltefosine for Children With PKDL Recruiting NCT02193022 Phase 3 Miltefosine
24 A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar Completed NCT00497601 Phase 2 Amphotericin B fat emulsion in visceral leishmaniasis;Amphotericin B fat emulsion;Amphotericin B in fat emulsion
25 Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa Completed NCT01067443 Phase 2 Liposomal amphotericin B (AmBisome®) and sodium stibogluconate;Liposomal amphotericin B + miltefosine;Miltefosine
26 Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa Completed NCT02431143 Phase 2 Miltefosine
27 Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar Completed NCT00371995 Phase 2 Liposomal amphotericin B and Miltefosine
28 Combination Chemotherapy for the Treatment of Indian Kala-Azar Completed NCT00370825 Phase 2 Combination therapy with AmBisome and miltefosine
29 A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis. Completed NCT00381394 Phase 2 sitamaquine
30 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2 Sodium Stibogluconate (SSG)
31 Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL) Completed NCT01635777 Phase 2 Miltefosine;Miltefosine
32 Use of Sodium Stibogluconate as a Treatment for Leishmaniasis Completed NCT00657618 Phase 1, Phase 2 Sodium Stibogluconate (SSG)
33 Short Course Regimens for Treatment of PKDL (Sudan) Recruiting NCT03399955 Phase 2 Paromomycin;Ambisome;Miltefosine
34 Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ Recruiting NCT02687971 Phase 2 Miltefosine
35 A Study of a New Leishmania Vaccine Candidate ChAd63-KH Active, not recruiting NCT02894008 Phase 2 ChAd63-KH
36 Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan Terminated NCT01980199 Phase 2 Fexinidazole
37 Miltefosine for Brazilian Visceral Leishmaniasis Terminated NCT00378495 Phase 1, Phase 2 Miltefosine: initially 2.5 mg/kg/day for 28 days
38 Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL Terminated NCT00832208 Phase 2 Liposomal amphotericin B (Ambisome);Liposomal amphotericin B (Ambisome)
39 SCH708980 With and Without AmBisome for Visceral Leishmaniasis Withdrawn NCT01437020 Phase 1, Phase 2 SCH708980 Anti-IL-10 monoclonal;AmBisome
40 Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India Completed NCT00486382 Phase 1
41 Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers Completed NCT02071758 Phase 1
42 Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL Completed NCT00982774 Phase 1
43 Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers Completed NCT01484548 Phase 1
44 Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition Recruiting NCT03636659 Phase 1 Amphotericin B Liposome;AmBisome (Amphotericin B) Liposome
45 Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine Unknown status NCT01138956 Not Applicable N-acetylcysteine;Pentavalent antimonial
46 Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia Completed NCT02148822
47 A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh Completed NCT01240473 Not Applicable Randomized trial for treatment of kala azar in Bangladesh
48 An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01328457 Not Applicable Paromomycin sulfate
49 Immunogenetics of Visceral Leishmaniasis Completed NCT00342823
50 Amphotericin B Treatment in Visceral Leishmaniasis Completed NCT00310505 Not Applicable Amphotericin B deoxycholate given as daily administration

Search NIH Clinical Center for Visceral Leishmaniasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: leishmaniasis, visceral

Genetic Tests for Visceral Leishmaniasis

Anatomical Context for Visceral Leishmaniasis

MalaCards organs/tissues related to Visceral Leishmaniasis:

41
Testes, Bone, T Cells, Bone Marrow, Spleen, Liver, Skin

Publications for Visceral Leishmaniasis

Articles related to Visceral Leishmaniasis:

(show top 50) (show all 1655)
# Title Authors Year
1
Meteorological conditions, elevation and land cover as predictors for the distribution analysis of visceral leishmaniasis in Sinkiang province, Mainland China. ( 30235597 )
2019
2
DNA prime-protein boost vaccine encoding HLA-A2, HLA-A24 and HLA-DR1 restricted epitopes of CaNA2 against visceral leishmaniasis. ( 30285279 )
2019
3
Andrographolide engineered gold nanoparticle to overcome drug resistant visceral leishmaniasis. ( 29421940 )
2018
4
Exploring sand fly salivary proteins to design multi-epitope subunit vaccine to fight against visceral leishmaniasis. ( 29377223 )
2018
5
Visceral leishmaniasis presenting with pancytopenia and circulating blastlike lymphocytes. ( 29930152 )
2018
6
Brain Parenchyma (pons) Involvement by Visceral Leishmaniasis: A Case Report. ( 29963097 )
2018
7
NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis. ( 29867949 )
2018
8
Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis. ( 29448040 )
2018
9
Combined neutralization of interferon gamma and tumor necrosis factor alpha induces IL-4 production but has no direct additive impact on parasite burden in splenic cultures of human visceral leishmaniasis. ( 29953494 )
2018
10
Visceral leishmaniasis in a patient with diabetes mellitus type 2 and discrete bicytopenia. ( 29375842 )
2018
11
Potential application of rLc36 protein for diagnosis of canine visceral leishmaniasis. ( 29412359 )
2018
12
Environmental factors associated with canine visceral leishmaniasis in an area with recent introduction of the disease in the State of Rio de Janeiro, Brazil. ( 29412315 )
2018
13
Canine Visceral Leishmaniasis; A Seroepidemiological Survey in Jiroft District, Southern Kerman Province, Southeastern Iran in 2015. ( 29963087 )
2018
14
Diagnostic lipid changes in patients with visceral leishmaniasis. ( 29848097 )
2018
15
Positive Influence of Behavior Change Communication on Knowledge, Attitudes, and Practices for Visceral Leishmaniasis/Kala-azar in India. ( 29386327 )
2018
16
High frequency of subclinical Leishmania infection among HIV-infected patients living in the endemic areas of visceral leishmaniasis in Fars province, southern Iran. ( 29860572 )
2018
17
Epidemiological aspects of human and canine visceral leishmaniasis in State of Alagoas, Northeast, Brazil. ( 29412243 )
2018
18
Sensitive and less invasive confirmatory diagnosis of visceral leishmaniasis in Sudan using loop-mediated isothermal amplification (LAMP). ( 29444079 )
2018
19
Correction: B Cell: T Cell Interactions Occur within Hepatic Granulomas during Experimental Visceral Leishmaniasis. ( 29894507 )
2018
20
Visceral leishmaniasis in an infant gorilla (Gorilla gorilla gorilla): Clinical signs, diagnosis, and successful treatment with single-dose liposomal amphotericin B. ( 29956831 )
2018
21
Molecular detection of Leishmania (Leishmania) infantum in phlebotomine sandflies from a visceral leishmaniasis endemic area in northwestern of SALo Paulo State, Brazil. ( 29373820 )
2018
22
The genetically determined production of the alarmin eosinophil-derived neurotoxin is reduced in visceral leishmaniasis. ( 29193305 )
2018
23
Liposomal Elongation Factor-1I+ Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis. ( 29441060 )
2018
24
Eosinophilic inflammation in lymph nodes of dogs with visceral leishmaniasis. ( 29920692 )
2018
25
Some aspects of entomological determinants of Phlebotomus orientalis in highland and lowland visceral leishmaniasis foci in northwestern Ethiopia. ( 29438419 )
2018
26
Immunohaematological and rheological parameters in canine visceral leishmaniasis. ( 29846458 )
2018
27
Description of Leishmania species among dogs and humans in Colombian Visceral Leishmaniasis outbreaks. ( 29936036 )
2018
28
Mediastinal cystic mass as atypical location of visceral leishmaniasis. ( 29398008 )
2018
29
Immunoprophylactic Potential of a Cocktail of Three Low Molecular Weight Antigens of <i>Leishmania donovani</i> along with Various Adjuvants Against Experimental Visceral leishmaniasis. ( 29963081 )
2018
30
Risk profile for Leishmania infection in dogs coming from an area of visceral leishmaniasis reemergence. ( 29406075 )
2018
31
Policy Recommendations From Transmission Modeling for the Elimination of Visceral Leishmaniasis in the Indian Subcontinent. ( 29860292 )
2018
32
Design of mannosylated oral amphotericin B nanoformulation: efficacy and safety in visceral leishmaniasis. ( 29385910 )
2018
33
Combination therapy with liposomal amphotericin b (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case. ( 29972577 )
2018
34
Serological diagnosis and prognostic of tegumentary and visceral leishmaniasis using a conserved Leishmania hypothetical protein. ( 29408435 )
2018
35
Efficacy of Meglumine Antimoniate under Low Polymerization State Orally Administrated in Murine Model of Visceral Leishmaniasis. ( 29866873 )
2018
36
Hemophagocytic Lymphohistiocytosis: A Confusing Problem of the Diagnosis of Visceral Leishmaniasis. ( 29398821 )
2018
37
Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: A candidate formulation for visceral leishmaniasis. ( 29864949 )
2018
38
Parasitic load and histological aspects in different regions of the spleen of dogs with visceral leishmaniasis. ( 29406277 )
2018
39
Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. ( 29534061 )
2018
40
Molecular Diagnosis of Visceral Leishmaniasis. ( 29922885 )
2018
41
Vaccination with a CD4<sup>+</sup> and CD8<sup>+</sup> T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis. ( 29908151 )
2018
42
Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis. ( 29911074 )
2018
43
Molecular Identification of Agents of Human Cutaneous Leishmaniasis and Canine Visceral Leishmaniasis in Different Areas of Iran Using Internal Transcribed Spacer 1 PCR-RFLP. ( 30123810 )
2018
44
Visceral Leishmaniasis Associated with Macrophage Activation Syndrome and Diffuse Alveolar Hemorrhage in a Lupus Patient. ( 30387429 )
2018
45
Hemophagocytic Lymphohistiocytosis Associated With Visceral Leishmaniasis. ( 29746438 )
2018
46
Demographic and clinical characterization of human visceral leishmaniasis in the State of Pernambuco, Brazil between 2006 and 2015. ( 30304268 )
2018
47
Seroprevalence and risk factors associated with canine visceral leishmaniasis in the State of Paraíba, Brazil. ( 30304279 )
2018
48
First autochthonous case of canine visceral leishmaniasis in Rondônia, Brazil, a region with no history of visceral leishmaniasis. ( 30304285 )
2018
49
Ecology and Molecular Detection of Leishmania infantum Nicolle, 1908 (Kinetoplastida: Trypanosomatida) in Wild-Caught Sand Flies (Psychodidae: Phlebotominae) Collected in Porto Alegre, Rio Grande do Sul: A New Focus of Visceral Leishmaniasis in Brazil. ( 30321358 )
2018
50
User and environment friendly direct agglutination test for the sero-diagnosis of visceral leishmaniasis: exclusion of formaldehyde and β-mercaptoethanol in test execution. ( 30325295 )
2018

Variations for Visceral Leishmaniasis

Expression for Visceral Leishmaniasis

Search GEO for disease gene expression data for Visceral Leishmaniasis.

Pathways for Visceral Leishmaniasis

Pathways related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 CXCL8 EEF2 IFNG IL10 IL2 IL27
2
Show member pathways
13.72 CXCL8 IFNG IL10 IL2 IL27 IL4
3
Show member pathways
13.45 CXCL8 IL10 IL2 IL4 TLR2 TLR4
4
Show member pathways
13.4 CXCL8 IFNG IL10 IL2 IL27 IL4
5
Show member pathways
13.25 IFNG IL2 IL4 TLR2 TLR4 TLR9
6
Show member pathways
13.05 CXCL8 IFNG IL10 IL2 NOS2 TLR2
7
Show member pathways
12.93 CXCL8 FOXP3 IFNG IL10 IL2 IL4
8
Show member pathways
12.86 CXCL8 IFNG IL2 IL4 TLR2 TLR4
9 12.85 CXCL8 IFNG IL2 IL4 NOS2
10
Show member pathways
12.74 IL2 TLR2 TLR4 TLR9 TNF
11
Show member pathways
12.67 IFNG IL10 IL2 IL4 TNF
12
Show member pathways
12.65 FOXP3 IFNG IL10 IL2 IL4 TLR2
13
Show member pathways
12.63 IFNG IL10 IL2 NOS2 TNF
14 12.59 FOXP3 IFNG IL10 IL2 IL4 TLR2
15
Show member pathways
12.49 IFNG IL10 IL2 IL4 TNF
16
Show member pathways
12.4 ALB IFNG IL2 IL4 TNF
17
Show member pathways
12.4 CXCL8 IFNG IL4 TLR2 TNF
18
Show member pathways
12.37 CXCL8 IFNG NOS2 TLR4 TNF
19
Show member pathways
12.34 CXCL8 TLR2 TLR4 TLR9 TNF
20
Show member pathways
12.33 CXCL8 IFNG IL10 IL2 IL4 TNF
21
Show member pathways
12.31 IFNG IL10 IL4 NOS2 TLR2 TLR4
22 12.27 IFNG NOS2 TLR2 TLR4 TLR9 TNF
23
Show member pathways
12.26 CXCL8 NOS2 TLR2 TNF
24
Show member pathways
12.25 IL10 IL2 TLR9 TNF
25 12.25 IFNG IL10 NOS2 TLR2 TLR4 TLR9
26
Show member pathways
12.13 IFNG IL4 TLR2 TLR4 TNF
27
Show member pathways
12.12 CXCL8 IFNG IL10 IL2 IL4
28 12.09 IFNG IL10 IL2 IL4 TNF
29
Show member pathways
12.08 IL2 TLR2 TLR4 TLR9
30 12.08 CXCL8 IL10 IL4 NOS2 TNF
31
Show member pathways
12.04 IFNG IL2 IL4 NOS2
32
Show member pathways
11.98 CXCL8 IFNG IL4 NOS2 TLR2 TLR4
33 11.96 CXCL8 IFNG TLR2 TLR4 TNF
34 11.94 CXCL8 IFNG IL2 IL4 NOS2 TLR4
35 11.92 IFNG NOS2 TLR4
36 11.91 CXCL8 IFNG NOS2 TLR4
37 11.9 IFNG IL10 IL2 IL4 TNF
38 11.89 CXCL8 TLR4 TNF
39 11.88 CXCL8 IL2 TLR4
40
Show member pathways
11.88 CXCL8 FOXP3 TLR4
41 11.88 CXCL8 IFNG IL2 IL4
42 11.87 CXCL8 IL10 NOS2 TLR4 TNF
43 11.85 IFNG IL10 IL2 TLR9 TNF
44 11.84 TLR2 TLR4 TLR9
45 11.78 CXCL8 IFNG IL10 NOS2 TLR2 TLR4
46
Show member pathways
11.76 CXCL8 IFNG IL2 NOS2 TNF
47
Show member pathways
11.76 CXCL8 FOXP3 IFNG IL2 IL4 TNF
48
Show member pathways
11.73 FOXP3 IL2 IL4
49 11.7 CXCL8 IL4 TNF
50 11.7 IFNG IL10 IL2 IL4 NOS2 TNF

GO Terms for Visceral Leishmaniasis

Cellular components related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 ALB CXCL8 IFNG IL10 IL2 IL27
2 extracellular region GO:0005576 9.32 ALB CXCL8 EEF2 IFNG IL10 IL2

Biological processes related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 TLR2 TLR4 TLR9 TNF
2 defense response to bacterium GO:0042742 9.97 IL10 NOS2 SLC11A1 TLR4 TLR9 TNF
3 response to bacterium GO:0009617 9.96 IL27 NOS2 SLC11A1 TLR4
4 defense response to Gram-negative bacterium GO:0050829 9.93 NOS2 SLC11A1 TLR4 TLR9
5 positive regulation of gene expression GO:0010628 9.92 FOXP3 IFNG IL4 SLC11A1 TLR2 TLR4
6 cellular response to interferon-gamma GO:0071346 9.91 NOS2 TLR2 TLR4
7 positive regulation of JNK cascade GO:0046330 9.9 TLR4 TLR9 TNF
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 IFNG IL2 IL4
9 regulation of insulin secretion GO:0050796 9.9 IFNG NOS2 TNF
10 positive regulation of interleukin-6 production GO:0032755 9.9 TLR2 TLR4 TLR9 TNF
11 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.89 TLR4 TLR9 TNF
12 positive regulation of tumor necrosis factor production GO:0032760 9.88 TLR2 TLR4 TLR9
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TLR2 TLR4 TLR9 TNF
14 negative regulation of tumor necrosis factor production GO:0032720 9.87 FOXP3 IL10 TLR4
15 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 IFNG TLR4 TNF
16 toll-like receptor signaling pathway GO:0002224 9.85 TLR2 TLR4 TLR9
17 lipopolysaccharide-mediated signaling pathway GO:0031663 9.85 TLR2 TLR4 TNF
18 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.84 TLR2 TLR4 TLR9
19 positive regulation of interferon-gamma production GO:0032729 9.84 IL2 SLC11A1 TLR4 TNF
20 negative regulation of interferon-gamma production GO:0032689 9.83 FOXP3 IL10 TLR4
21 positive regulation of interferon-beta production GO:0032728 9.83 TLR2 TLR4 TLR9
22 positive regulation of inflammatory response GO:0050729 9.83 IL2 TLR2 TLR4 TLR9 TNF
23 positive regulation of interleukin-10 production GO:0032733 9.81 TLR2 TLR4 TLR9
24 positive regulation of B cell proliferation GO:0030890 9.81 IL2 IL4 TLR4 TLR9
25 regulation of regulatory T cell differentiation GO:0045589 9.8 FOXP3 IFNG IL2
26 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.8 TLR2 TLR4 TLR9
27 regulation of cytokine secretion GO:0050707 9.79 TLR2 TLR4 TLR9
28 I-kappaB phosphorylation GO:0007252 9.77 TLR2 TLR4 TLR9
29 negative regulation of interleukin-17 production GO:0032700 9.76 FOXP3 IFNG TLR4
30 positive regulation of interleukin-8 production GO:0032757 9.76 TLR2 TLR4 TLR9 TNF
31 inflammatory response GO:0006954 9.76 CXCL8 IL10 IL27 SLC11A1 TLR2 TLR4
32 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.74 TLR4 TLR9 TNF
33 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.73 IL27 TLR9
34 positive regulation of regulatory T cell differentiation GO:0045591 9.73 FOXP3 IL2
35 macrophage activation GO:0042116 9.73 SLC11A1 TLR4
36 cellular response to lipoteichoic acid GO:0071223 9.73 TLR2 TLR4
37 positive regulation of isotype switching to IgG isotypes GO:0048304 9.72 IL2 IL4
38 endothelial cell apoptotic process GO:0072577 9.72 IL10 TNF
39 negative regulation of T-helper 17 cell differentiation GO:2000320 9.72 FOXP3 IL2
40 positive regulation of interferon-beta biosynthetic process GO:0045359 9.71 TLR4 TLR9
41 negative regulation of interleukin-8 production GO:0032717 9.71 IL10 TLR9
42 negative regulation of cytokine secretion involved in immune response GO:0002740 9.71 IL10 TNF
43 negative regulation of lymphocyte proliferation GO:0050672 9.71 FOXP3 IL2
44 positive regulation of interleukin-12 production GO:0032735 9.71 IFNG TLR2 TLR4 TLR9
45 positive regulation of interleukin-18 production GO:0032741 9.7 TLR2 TLR9
46 tumor necrosis factor production GO:0032640 9.7 TLR2 TLR9
47 positive regulation of killing of cells of other organism GO:0051712 9.69 IFNG NOS2
48 positive regulation of toll-like receptor signaling pathway GO:0034123 9.69 TLR2 TLR9
49 regulation of isotype switching GO:0045191 9.68 IL10 IL4
50 type 2 immune response GO:0042092 9.68 IL10 IL4

Molecular functions related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CXCL8 IFNG IL10 IL2 IL27 IL4
2 signaling pattern recognition receptor activity GO:0008329 9.16 TLR2 TLR9
3 lipopolysaccharide receptor activity GO:0001875 8.96 TLR2 TLR4

Sources for Visceral Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....